Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer
The FDA Approval of Atezolizumab in Bladder CancerПодробнее
Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder CancerПодробнее
FDA Approval of Atezolizumab for Advanced Bladder CancerПодробнее
Dr. Steinberg Discusses the Challenges in Treating Bladder CancerПодробнее
Dr. Rosenberg on Immunotherapeutic Advances in Bladder CancerПодробнее
Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLCПодробнее
Dr. Rosenberg on Future Use of Atezolizumab in Bladder CancerПодробнее
Dr. Gary Steinberg on New AUA Guidelines for Bladder CancerПодробнее
Dr. Steinberg on the Standard of Care in Non-Muscle Invasive Bladder CancerПодробнее
Dr. Petrylak on Atezolizumab in Bladder CancerПодробнее
Impact of Immunotherapy on Bladder CancerПодробнее
Dr. Garcia on FDA Approval of Pembrolizumab in Bladder CancerПодробнее
FDA Approval of Durvalumab for Bladder CancerПодробнее
Dr. Petrylak on FDA Approval of Nivolumab in Bladder CancerПодробнее
Atezolizumab limits disease progression for metastatic urothelial bladder cancerПодробнее
Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder CancerПодробнее
Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder CancerПодробнее
Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder CancerПодробнее
Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancerПодробнее
